Trump Administration Funds New Research into Psychedelic Drug Ibogaine
The Chattanooga Times Free Press reports on the Trump administration's decision to fund new research into the controversial psychedelic drug ibogaine.
Chattanooga, TN, November 12, 2026 —
The Trump administration has allocated funding for new research into the psychedelic substance ibogaine, according to a report by the Chattanooga Times Free Press. The decision marks a step into investigating a drug that is considered controversial due to its complex effects and potential risks.
Details regarding the specific nature of the research, including the institutions or researchers involved, the amount of funding allocated, or the precise timeline for the studies, were not provided in the report. The Chattanooga Times Free Press highlighted the administration’s move to explore the therapeutic potential of ibogaine, a substance derived from the West African iboga plant.
Ibogaine has been the subject of discussion and study for its potential to treat addiction, particularly opioid dependence. However, its use is also associated with significant safety concerns, including potential cardiac side effects and psychoactive properties that require careful medical supervision. Due to these factors, ibogaine is classified as a Schedule I controlled substance in the United States, meaning it is deemed to have a high potential for abuse and no currently accepted medical use in treatment.
The decision to fund research into ibogaine indicates a growing interest from federal bodies in exploring alternative or novel treatments for conditions such as addiction. The extent to which this research will clarify the drug’s efficacy and safety profile remains to be seen. Further details on the scope and objectives of the funded research are anticipated.
Story summarized from the original created by Google News on news.google.com, see more information here.
